



EI125463537US

A061CIP1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not Yet Assigned  
Group Art Unit : 1645  
Applicants : Gregory R. Mundy et al.  
Application No. : 09/943,659  
Confirmation No. : 2421  
Filed : August 31, 2001  
For : METHODS OF TREATING MULTIPLE MYELOMA  
AND MYELOMA-INDUCED BONE RESORPTION  
USING INTEGRIN ANTAGONISTS

New York, New York  
December 5, 2001

Hon. Commissioner for Patents  
Washington, D.C. 20231

TRANSMITTAL LETTER FOR  
INFORMATION DISCLOSURE STATEMENT

Sir:


Transmitted herewith is an Information Disclosure Statement in the above-identified application. This Statement is submitted:

[ ] within three months of the application filing date;

[X] more than three months from the application filing date but before the mailing date of the first Office Action on the merits.

In accordance with 37 C.F.R. § 1.97, submission of this Statement requires no fee. However, if for any reason a fee is due, the Director is hereby authorized to charge payment of any fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.

Respectfully submitted,



James F. Haley, Jr. (Reg. No. 27,794)  
Attorney for Applicants  
Stanley D. Liang (Reg. No. 43,753)  
Agent for Applicants

FISH & NEAVE  
Customer No. 1473  
1251 Avenue of the Americas  
New York, New York 10020-1104  
Tel.: (212) 596-9000  
Fax: (212) 596-9090



EI125463537US

A061CIP1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not Yet Assigned  
Group Art Unit : 1645  
Applicants : Gregory R. Mundy et al.  
Application No. : 09/943,659  
Confirmation No. : 2421  
Filed : August 31, 2001  
For : METHODS OF TREATING MULTIPLE MYELOMA  
AND MYELOMA-INDUCED BONE RESORPTION  
USING INTEGRIN ANTAGONISTS

New York, New York  
December 5, 2001

Hon. Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b),  
applicants, through their attorney and agent, make of record  
the following documents:<sup>1</sup>

---

<sup>1</sup> For the Examiner's convenience, applicants have enclosed a completed Form PTO-1449, listing these documents.

U.S. PATENTS

5,510,332 (Kogan et al.), issued April 23, 1996.

FOREIGN PATENT APPLICATIONS AND PUBLICATIONS

WO 99/61421, Published December 2, 1999.

WO 00/15247, Published March 23, 2000.

WO 01/12186, published February 22, 2001.

OTHER REFERENCES

Masellis-Smith et al. "Adhesion of Multiple Myeloma Peripheral B Cells to Bone Marrow Fibroblasts: A Requirement for CD44 and alphabeta7", Cancer Research 57(5) : 930-936 (1997).

Roodman GD "Mechanisms of Bone Lesions in Multiple Myeloma and Lymphoma", Database Medline Online! US National Library of Medicine (NLM), Bethesda, MD, retrieved from STN, Database accession no. 1998026745, abstract

Roodman GD "Mechanisms of Bone Lesions in Multiple Myeloma and Lymphoma", Cancer 80 (8 Suppl): 1557-1563 (1997, Oct. 15).

Akatsu et al. "Chinese Hamster Ovary Cells Expressing Alpha4beta1 Integrin Stimulate Osteoclast Formation In Vitro", Database BIOSIS Online! Biosciences Information Service, Philadelphia, PA (August 1998) Database accession no. PREV199800429141, abstract.

Akatsu et al. "Chinese Hamster Ovary Cells Expressing Alpha4beta1 Integrin Stimulate Osteoclast Formation In Vitro", Journal of Bone and Mineral Research 13 (8) : 1251-1259 (1998).

Michigami et al. "Interactions of Myeloma Cells with Bone Marrow Stromal Cells via Alpha4 Beta 1 Integrin - VCAM-1 is required for the Development of Osteolysis", Database SCISEARCH

Online!, retrieved from STN, Database accession no. 684996

Michigami et al. "Interactions of Myeloma Cells with Bone Marrow Stromal Cells via Alpha4Beta 1 Integrin-VCAM-1 is required for the Development of Osteolysis", Journal of Bone and Mineral Research 12 Supp. '1!, pp. 104 (1997).

Mori et al. "Anti-alpha4 Integrin Antibody Suppresses the Bone Disease of Myeloma and Disrupts Myeloma-marrow Stromal Cell Interactions", Journal of Bone and Mineral Research 14 Supp. '1!, pp. 1161 (1999).

REMARKS

The above-cited documents, with the exception of two (WO 00/15247 and WO 01/12186), were cited in the International Search Report of PCT application number PCT/US99/21170, a parent application of the above-identified application.

Applicants respectfully request that the above-cited documents be (1) fully considered by the Examiner during the course of the examination of this application and (2) printed on any patent issuing from this application. Applicants also request that a copy of the enclosed Form PTO-1449, duly initialed by the Examiner, be forwarded to the undersigned with the next official communication.

Applicants request favorable action in this application.

Respectfully submitted,



---

James F. Haley, Jr. (Reg. No. 27,794)  
Attorney for Applicants  
Stanley D. Liang (Reg. No. 43,753)  
Agent for Applicants

FISH & NEAVE  
Customer No. 1473  
1251 Avenue of the Americas  
New York, New York 10020-1104  
Tel.: (212) 596-9000  
Fax: (212) 596-9090



12-10-01

✓ Sector 5  
X 58

A061CIP

Examiner : Not Yet Assigned  
Group : 1645  
Applicants : Gregory R. Mundy et al.  
Application No. : 09/943,659  
Confirmation No. : 2421  
Filing Date : August 31, 2001  
Title : METHODS OF TREATING MULTIPLE MYELOMA  
AND MYELOMA-INDUCED BONE RESORPTION  
USING INTEGRIN ANTAGONISTS

“Express Mail” mailing label number: EI125463537US


Date of Deposit: December 5, 2001

I hereby certify that this paper/fee is being deposited with the United States Postal Service “EXPRESS MAIL POST OFFICE TO ADDRESSEE” service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Hon. Commissioner for Patents, P.O. Box 2327, Arlington, VA 22202.

Lillian Garcia  
Lillian Garcia

Encl:

Transmittal Letter For Information Disclosure Statement (in duplicate); Information Disclosure Statement; PTO-Form 1449 (in duplicate) (and reference cited therein); a Response to Notice to File Missing Parts (in duplicate) (including a Copy of the Notice to File Missing Parts); an Executed Declaration and Power of Attorney; Substitute Drawings; a Check for \$130; a post card.



EI125463537US

#5

Sheet 1 of 2

FORM PTO-149 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. A061CIP1	APPLICATION NO. 09/943,659
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANTS Gregory R. Mundy et al.	
		FILING DATE August 31, 2001	GROUP 1645

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,510,332	4/23/96	Kogan et al.	514	14	July 7, 1994

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 99/61421	12/2/99	PCT	C07D	207/16		
	WO 00/15247	3/23/00	PCT	A61K	38/17		
	WO 01/12186	2/22/01	PCT	A61K	31/40		

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Masellis-Smith et al. "Adhesion of Multiple Myeloma Peripheral B Cells to Bone Marrow Fibroblasts: A Requirement for CD44 and alphabeta7", <u>Cancer Research</u> 57(5): 930-936 (1997).
	Roodman GD "Mechanisms of Bone Lesions in Multiple Myeloma and Lymphoma", <u>Database Medline Online! US National Library of Medicine (NLM), Bethesda, MD</u> , retrieved from STN, Database accession no. 1998026745, abstract.
	Roodman GD "Mechanisms of Bone Lesions in Multiple Myeloma and Lymphoma", <u>Cancer</u> 80 (8 Suppl): 1557-1563 (1997, Oct. 15).
	Akatsu et al. "Chinese Hamster Ovary Cells Expressing Alpha4beta1 Integrin Stimulate Osteoclast Formation In Vitro", <u>Database BIOSIS Online! Biosciences Information Service, Philadelphia, PA</u> (August 1998) Database accession no. PREV199800429141, abstract.
	Akatsu et al. "Chinese Hamster Ovary Cells Expressing Alpha4beta1 Integrin Stimulate Osteoclast Formation In Vitro", <u>Journal of Bone and Mineral Research</u> 13 (8): 1251-1259 (1998).
	Michigami et al. "Interactions of Myeloma Cells with Bone Marrow Stromal Cells via Alpha4 Beta 1 Integrin - VCAM-1 is required for the Development of Osteolysis", <u>Database SCISEARCH Online!</u> , retrieved from STN, Database accession no. 684996.
	Michigami et al. "Interactions of Myeloma Cells with Bone Marrow Stromal Cells via Alpha4 Beta 1 Integrin - VCAM-1 is required for the Development of Osteolysis", <u>Journal of Bone and Mineral Research</u> 12 Supp. '1!, pp. 104 (1997).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

O I P E  
DEC 05 2001  
JC32Sheet 2 of 2

FORM PTO-1449

U. S. DEPARTMENT OF COMMERCE  
PATENT & TRADEMARK OFFICEINFORMATION DISCLOSURE  
STATEMENT BY APPLICANTATTY. DOCKET NO.  
A061CIP1APPLICATION NO.  
09/943,659APPLICANTS  
Gregory R. Mundy et al.FILING DATE  
August 31, 2001GROUP  
1645

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Mori et al. "Anti-alpha4 Integrin Antibody Suppresses the Bone Disease of Myeloma and Disrupts Myeloma-marrow Stromal Cell Interactions", <u>Journal of Bone and Mineral Research</u> 14 Supp. '11, pp. 1161 (1999).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.